Department of Laboratory Medicine, Translational Research Center Karolinska (TRACK), Karolinska Institutet, Karolinska University Hospital, SE-14186 Huddinge, Sweden.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Nucleic Acid Ther. 2023 Apr;33(2):117-131. doi: 10.1089/nat.2022.0046. Epub 2023 Feb 3.
Huntington's disease is a neurodegenerative, trinucleotide repeat (TNR) disorder affecting both males and females. It is caused by an abnormal increase in the length of CAG•CTG TNR in exon 1 of the gene (). The resultant, mutant HTT mRNA and protein cause neuronal toxicity, suggesting that reduction of their levels would constitute a promising therapeutic approach. We previously reported a novel strategy in which chemically modified oligonucleotides (ONs) directly target chromosomal DNA. These anti-gene ONs were able to downregulate both mRNA and protein. In this study, various locked nucleic acid (LNA)/DNA mixmer anti-gene ONs were tested to investigate the effects of varying ON length, LNA content, and fatty acid modification on expression. Altering the length did not significantly influence the ON potency, while LNA content was critical for activity. Utilization of palmitoyl-modified LNA monomers enhanced the ON activity relatively to the corresponding nonmodified LNA under serum starvation conditions. Furthermore, the number of palmitoylated LNA monomers and their positioning greatly affected ON potency. In addition, we performed RNA sequencing analysis, which showed that the anti-gene ONs affect the "immune system process, mRNA processing, and neurogenesis." Furthermore, we observed that for repeat containing genes, there is a higher tendency for antisense off-targeting. Taken together, our findings provide an optimized design of anti-gene ONs that could potentially be developed as DNA-targeting therapeutics for this class of TNR-related diseases.
亨廷顿病是一种影响男性和女性的神经退行性三核苷酸重复(TNR)疾病。它是由基因()外显子 1 中 CAG•CTG TNR 的异常增加引起的。由此产生的突变 HTT mRNA 和蛋白引起神经元毒性,这表明降低其水平将构成一种有前途的治疗方法。我们之前报道了一种新的策略,即化学修饰的寡核苷酸(ONs)直接靶向染色体 DNA。这些反基因 ONs 能够下调 mRNA 和蛋白。在这项研究中,测试了各种锁核酸(LNA)/DNA 混合反基因 ONs,以研究改变 ON 长度、LNA 含量和脂肪酸修饰对表达的影响。改变长度对 ON 效力没有显著影响,而 LNA 含量对活性至关重要。在血清饥饿条件下,使用棕榈酰修饰的 LNA 单体增强了 ON 的活性,相对于相应的非修饰 LNA。此外,棕榈酰化 LNA 单体的数量及其定位对 ON 效力有很大影响。此外,我们进行了 RNA 测序分析,结果表明反基因 ONs 影响“免疫系统过程、mRNA 处理和神经发生”。此外,我们观察到对于含有重复序列的基因,反义脱靶的趋势更高。总之,我们的研究结果提供了一种优化的反基因 ON 设计,可能会开发为针对这类 TNR 相关疾病的 DNA 靶向治疗药物。